Skip to Content

Eyelash Lengthener

February 24, 2009

Women who want longer lashes now have an alternative to messy mascara. Latisse, a version of a drug developed for glaucoma, was recently approved by the U.S. Food and Drug Administration to promote eyelash growth. Latisse is dabbed along the base of the eyelashes and must be applied daily, or its lash-­thickening effect will wear off. Available only by prescription, it has some potential side effects, including eye redness, itchy eyes, and discoloration of the eyelid.

Courtesy of Allergan

Product: Latisse

Cost: $120 for a 30-day supply

Source: www.latisse.com

Company: Allergan

Other products in this section:

180° Surveillance Camera

Volume-Limiting Headphones

3-D Webcam

Keep Reading

Most Popular

transplant surgery
transplant surgery

The gene-edited pig heart given to a dying patient was infected with a pig virus

The first transplant of a genetically-modified pig heart into a human may have ended prematurely because of a well-known—and avoidable—risk.

open sourcing language models concept
open sourcing language models concept

Meta has built a massive new language AI—and it’s giving it away for free

Facebook’s parent company is inviting researchers to pore over and pick apart the flaws in its version of GPT-3

Muhammad bin Salman funds anti-aging research
Muhammad bin Salman funds anti-aging research

Saudi Arabia plans to spend $1 billion a year discovering treatments to slow aging

The oil kingdom fears that its population is aging at an accelerated rate and hopes to test drugs to reverse the problem. First up might be the diabetes drug metformin.

images created by Google Imagen
images created by Google Imagen

The dark secret behind those cute AI-generated animal images

Google Brain has revealed its own image-making AI, called Imagen. But don't expect to see anything that isn't wholesome.

Stay connected

Illustration by Rose WongIllustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.